In pharma marketing, HCP digital reach has become a defining metric. Media plans are often evaluated by how many healthcare professionals (HCPs) you can reach and at what cost. On the surface, it makes sense—maximize exposure, minimize spend, and expect performance to follow.
But in point-of-care (POC) marketing, that equation is incomplete. Focusing on reach and cost alone can actually undermine campaign effectiveness and introduce risks that go beyond performance.
For pharma marketers and media buyers, the real opportunity lies in rethinking what “value” means in POC. Because in this environment, how and where you reach HCPs matters just as much as how many you reach.
When evaluating POC vendors, it’s common to prioritize high list match rates and low CPMs. These metrics signal efficiency and scale. But they don’t guarantee impact.
The core issue: optimizing for scale often sacrifices precision.
Campaigns built around maximum reach can lead to several unintended consequences:
In other words, you may achieve impressive HCP reach—but fail to influence prescribing behavior.
This is especially critical at the point of care, where the value of media is tied directly to its proximity to decision-making. If your message isn’t delivered when an HCP is diagnosing, evaluating treatment options, or prescribing, its impact drops significantly.
High reach does not equal high relevance. And relevance is what drives script lift.
POC marketing is fundamentally different from traditional digital channels. It operates within clinical workflows, where timing and context are everything.
Rather than asking, “How many HCPs did we reach?”, the better question is: “Did we reach the right HCPs at the moment they could act?”
This shift reframes HCP reach from a volume metric to a quality metric.
And that’s where transparency becomes essential.
If reach tells you how much, transparency tells you how well. But transparency at the point of care isn’t always a given. Many solutions aggregate multiple channels (EHR, programmatic, social, etc.) into a single “POC” offering. While this can simplify buying, it can also obscure critical details:
Without this visibility, you’re left making assumptions about performance—and paying premium POC rates for potentially non-POC tactics.
For pharma marketers, the stakes extend beyond campaign impact. Transparency is also a compliance requirement.
MLR-approved campaigns depend on clearly defined targeting, messaging, and activation parameters. If you cannot verify:
…you introduce risk.
A lack of transparency can make it impossible to validate adherence to brand standards, raising concerns with regulators and internal stakeholders alike.
This is a critical but often overlooked dimension of HCP digital reach: It’s not just about reaching HCPs—it’s about proving you reached them correctly.
Optimizing HCP digital reach isn’t about bigger numbers. It’s about smarter ones. In POC marketing, value comes from the intersection of:
When all three are present, campaigns don’t just deliver impressions—they influence decisions. And that’s the real goal.
To capture the full value of POC marketing, pharma marketers and media buyers need to evolve their evaluation criteria. Here’s what to prioritize:
If the answer to any of these is “no,” you may be optimizing for reach—but not for impact.
Point-of-care marketing sits closer to prescribing than any other channel in the media mix. But that proximity only matters if you can harness it effectively.
Reach and cost will always be part of the equation. But without transparency, they’re incomplete—and potentially misleading.
For pharma marketers looking to drive measurable script impact, the path forward is clear:
Don’t just ask how many HCPs you reached. Ask whether you can prove it mattered.